While it is not clear whether PXR can regulate CD36 expression in human monocytes or macrophages, future studies are needed to investigate the detailed mechanisms through which PXR-agonistic EDCs regulate CD36 expression in human monocytes or macrophages to affect atherosclerosis development and CVD risk. Here, NR1I2 is linked to atherosclerosis.